Posts tagged prostate
Profound Medical sells first TULSA-PRO in Finland

Profound Medical (OTCQX:PRFMF; TSXV:PRN) has successfully completed the first sale of a TULSA-PRO system in Finland to the Turku University Hospital, in collaboration with Royal Philips, who is working in partnership with Profound to commercialize the TULSA-PRO system in Europe.

Read More
GeneNews in pact with large physician group

GeneNews (TSX:GEN) has signed an agreement with a large, multi-specialty physician group in the American Midwest for use of its cancer diagnostic tests.

Read More
Profound Medical to list on OTCQX

Shares of Profound Medical (TSX-V:PRN) will be eligible for trading on the OTCQX Best Market under the symbol, PRFMF, effective at the open on March 13.

Read More
Profound Medical COO joins XOR-Labs board

Steven Plymale, president and COO of Profound Medical (TSX-V:PRN), has been appointed an independent director of XOR-Labs, a spinoff from Toronto General Hospital at University Health Network, the world's leading center for lung transplantation and a MaRS Innovation company.

Read More
Prostate cancer study shows benefit of 3DS’ telomere signature analysis

Data from a new study published recently in Urologic Oncology involving men with localized high-risk prostate cancer suggests that the use of 3D Signatures’ (OTCQB:TDSGF; TSX-V:DXD) technology platform, TeloView, may be a promising blood-based treatment-response biomarker in prostate cancer patients who are undergoing combined androgen deprivation therapy (ADT) and radiation therapy (RT).

Read More
3D Signatures included in PRECISE prostate cancer trial

3D Signatures (TSX-V:DXD) announced its participation in a major clinical trial for prostate cancer diagnosis and management, known as PRECISE, marking the company's first step toward validation and approval of clinical risk assessment tests for prostate cancer.

PRECISE is led by renowned uro-oncologist and prostate cancer thought leader, Dr. Laurence Klotz, who is chairman of the Canadian Urology Research Consortium, the study sponsor.

Read More
Roth starts Biocept at buy

Roth Capital Partners has initiated coverage on Biocept (NASDAQ:BIOC) with a “buy” rating and target price of $1.20. The stock closed at 63 cents on Monday.

“Through its proprietary technology platform capable of assaying both circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA), strong IP portfolio, notable collaborations with leading cancer institutions, and building commercial momentum, we believe Biocept is uniquely positioned as a leader in the emerging field of liquid biopsy and personalized medicine,” writes analyst Chris Lewis.

Read More